Primary Care POC Diagnostics Market Insights Highlight Segment Expansion And Market Leadership

The primary care point-of-care (POC) diagnostics market is poised for substantial expansion as healthcare continues to evolve toward more accessible and efficient testing solutions. With advancements in technology and growing demand for rapid diagnostics, this sector is set to play an increasingly vital role in patient care over the coming years. Below is an in-depth look at the market's size, influential players, emerging trends, and segmentation details.

Steady Growth Forecast for the Primary Care POC Diagnostics Market Size
The primary care POC diagnostics market is projected to experience robust growth, reaching a valuation of $24.6 billion by 2030. This represents a compound annual growth rate (CAGR) of 7.3%. Several factors contribute to this upward trajectory, including a greater emphasis on decentralized diagnostic testing, the integration of AI-powered diagnostic tools, the surge in telehealth-enabled testing services, increased focus on preventive health screening, and rising investments in personalized diagnostic technologies. Notable trends expected to shape this market include a wider adoption of rapid diagnostic tests, enhanced use of digital POC devices, growing demand for home-use diagnostic kits, expansion of multiplex testing platforms, and a stronger emphasis on early detection of diseases.

The primary care poc diagnostics market size has grown strongly in recent years. It will grow from $17.38 billion in 2025 to $18.59 billion in 2026 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing prevalence of infectious and chronic diseases, wider adoption of glucose and cardiometabolic testing, expansion of primary care diagnostic capabilities, increased use of otc diagnostic products, improved accessibility of rapid tests.

Download a free sample of the primary care poc diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15642&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Organizations Steering the Primary Care POC Diagnostics Market
Key companies that dominate this market include Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Becton, dic*kinson and Company, bioMerieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Nova Biomedical Corporation, Randox Laboratories Ltd, Ortho Clinical Diagnostics, Nipro Corporation, OraSure Technologies, Meridian Bioscience Inc, DiaSorin SpA, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Fujirebio Diagnostics Inc., Immunodiagnostic Systems Holdings PLC, Quotient Limited, AccuBioTech Co. Ltd., and bioMedomics Inc.

Strategic Acquisition to Strengthen Diagnostic Capabilities
In a significant move during July 2024, Switzerland-based pharmaceutical giant F. Hoffmann-La Roche Ltd. acquired LumiraDx's point-of-care technology from LumiraDx for $350 million. This strategic acquisition aims to bolster Roche's diagnostic portfolio and enhance access to decentralized testing solutions, particularly in primary care environments and low- to middle-income countries. LumiraDx, headquartered in the UK, specializes in point-of-care diagnostics with a mission to transform healthcare delivery in community settings.

View the full primary care poc diagnostics market report:
https://www.thebusinessresearchcompany.com/report/primary-care-poc-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Progressive Trends Defining Opportunities in Primary Care POC Diagnostics
Companies in this space are investing heavily in microfluidic-based rapid susceptibility testing, designed to speed up antibiotic decision-making at the point of care. Microfluidic technology leverages miniature fluid channels to quickly isolate and cultivate bacteria, enabling faster evaluation of antibiotic effectiveness and reducing diagnostic wait times. For example, in June 2023, Japan-based diagnostic firm Sysmex Corporation unveiled the PA-100 AST System, which utilizes proprietary microfluidic technology to detect bacteria in urine samples within 15 minutes and provide antimicrobial susceptibility test results in as few as 30 minutes during the initial patient visit. This desktop-sized analyzer operates with reagent cartridges into which samples are placed directly, allowing healthcare staff without specialized lab training to perform the tests easily. By accelerating diagnosis, this device helps ensure timely and appropriate antibiotic usage, supporting global efforts to combat antimicrobial resistance.

Market Segmentation Highlighting the Largest Share in Primary Care POC Diagnostics
The primary care POC diagnostics market is segmented into several key categories as follows:

By Product Type:
- Glucose Monitoring
- Cardiometabolic Testing Products
- Infectious Disease Testing Products
- Coagulation Testing Products
- Pregnancy and Fertility Testing Products
- Tumor or Cancer Marker Testing Products
- Cholesterol Testing Products
- Hematology Testing Products
- Drug-of-Abuse (DOA) Testing Products
- Other Products

By Prescription Type:
- Prescription Based
- Over-The-Counter (OTC) Testing

By End-Use Settings:
- Hospitals
- Diagnostic Centers
- Research Laboratories
- Home-Care Settings
- Other End-Uses

Further breakdown within segments includes subcategories such as:

Glucose Monitoring sub-segments: Blood glucose meters, continuous glucose monitoring systems, test strips, and glucose control solutions.

Cardiometabolic Testing sub-segments: Blood pressure monitors, lipid profile kits, Hemoglobin A1c kits, ECG monitors, and point-of-care Hemoglobin A1c devices.

Infectious Disease Testing sub-segments: Rapid strep tests, influenza kits, COVID-19 rapid tests, HIV rapid tests, hepatitis kits, malaria rapid diagnostic tests, among others.

Coagulation Testing sub-segments: Prothrombin time kits, INR monitors, activated partial thromboplastin time kits, coagulation control solutions, whole blood coagulation monitors.

Pregnancy and Fertility Testing sub-segments: Home urine pregnancy tests, ovulation prediction kits, pregnancy test strips, fertility monitoring devices.

Tumor or Cancer Marker Testing sub-segments: PSA testing kits, carcinoembryonic antigen kits, CA-125 kits, HER2 testing kits, and other tumor markers.

Cholesterol Testing sub-segments: Total cholesterol kits, LDL/HDL kits, triglyceride kits, point-of-care lipid panel devices.

Hematology Testing sub-segments: Hemoglobin test kits, hematocrit kits, complete blood count kits, hematology analyzers, Hemoglobin A1c devices.

Drug-of-Abuse Testing sub-segments: Urine drug tests, oral fluid tests, saliva-based tests, blood-based tests, breath alcohol tests.

Other Products sub-segments: Allergy test kits, urinalysis strips, vitamin and mineral deficiency kits, liver function tests, kidney function testing products, blood gas analyzers.

This detailed segmentation underscores the diverse range of diagnostic tools and tests that cater to various clinical and home-care needs, reflecting the expanding scope and complexity of the primary care POC diagnostics market.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.